A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer

被引:19
|
作者
Bilgi Kamac, Melike [1 ]
Altun, Muhammed [1 ]
Yilmaz, Merve [1 ]
Sezginturk, Mustafa Kemal [2 ]
机构
[1] Cankiri Karatekin Univ, Fac Sci, Chem Dept, TR-18100 Cankiri, Turkiye
[2] Canakkale Onsekiz Mart Univ, Fac Engn, Bioengn Dept, Canakkale, Turkiye
关键词
CA125; HE4; Simultaneous determination; Dual electrochemical immunosensors; Ovarian cancer; ANTIGEN; 125; BIOSENSOR; DISEASE; PROTEIN; POINT; PREDICTION; MULTIPLE; MARKER; SIGNAL; RISK;
D O I
10.1007/s00216-023-04569-y
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The blood levels of cancer antigen 125 (CA125) and human epididymal secretory protein 4 (HE4) are measured in the diagnosis and progression monitoring of ovarian cancer (OC), and the Risk of Ovarian Malignancy Algorithm (ROMA) score% values are calculated for cancer risk assessment. For the first time, disposable dual screen-printed carbon electrodes modified with reduced graphene oxide, polythionine, and gold nanoparticles were used to fabricate label-free electrochemical dual CA125-HE4 immunosensors for the sensitive, fast, and practical simultaneous determination of CA125 and HE4. DPV and SWV methods were used to simultaneously determine antigens in two different linear ranges (1-100 pg mL(-1) and 1-50 ng mL(-1)). High sensitivity, low LOD, and LOQ were obtained for two linear ranges with a correlation coefficient above 0.99. The application stability of the dual CA125-HE4 immunosensors was determined as 60 days, and the storage stability was determined as 16 weeks. The dual immunosensors exhibited high selectivity in eight different antigen mixtures. The reusability of the dual immunosensors has been tested up to 9 cycles. ROMA score% values for pre-menopausal and post-menopausal status were calculated using the concentration of CA125 and HE4 in the blood serum and assessing OC risk. The disposable dual immunosensors can be used in point-of-care tests for rapid and practical simultaneous determination of CA125 and HE4 with high selectivity, sensitivity, and repeatability.
引用
收藏
页码:1709 / 1718
页数:10
相关论文
共 50 条
  • [31] Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
    Hamed, Elham O.
    Ahmed, Hydi
    Sedeek, Osama B.
    Mohammed, Abeer M.
    Abd-Alla, Ali A.
    Ghaffar, Hazem M. Abdel
    DIAGNOSTIC PATHOLOGY, 2013, 8
  • [32] The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis
    Li, Y.
    Wang, Z. -C
    Luo, L.
    Mu, C. -Y.
    Xu, J.
    Feng, Q.
    Li, S. -B.
    Gu, B.
    Ma, P.
    Lan, T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (02) : 604 - 610
  • [33] Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer
    Kristjansdottir, Bjorg
    Levan, Kristina
    Partheen, Karolina
    Sundfeldt, Karin
    GYNECOLOGIC ONCOLOGY, 2013, 131 (01) : 52 - 58
  • [34] Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125
    Shah, Chirag A.
    Lowe, Kimberly A.
    Paley, Pamela
    Wallace, Erin
    Anderson, Garnet L.
    McIntosh, Martin W.
    Andersen, M. Robyn
    Scholler, Nathalie
    Bergan, Lindsay A.
    Thorpe, Jason D.
    Urban, Nicole
    Drescher, Charles W.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (05) : 1365 - 1372
  • [35] Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Jorge A. Alegría-Baños
    José C. Jiménez-López
    Arely Vergara-Castañeda
    David F. Cantú de León
    Alejandro Mohar-Betancourt
    Delia Pérez-Montiel
    Gisela Sánchez-Domínguez
    Mariana García-Villarejo
    César Olivares-Pérez
    Ángel Hernández-Constantino
    Acitlalin González-Santiago
    Miguel Clara-Altamirano
    Liz Arela-Quispe
    Diddier Prada-Ortega
    Journal of Ovarian Research, 14
  • [36] Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Alegria-Banos, Jorge A.
    Jimenez-Lopez, Jose C.
    Vergara-Castaneda, Arely
    Cantu de Leon, David F.
    Mohar-Betancourt, Alejandro
    Perez-Montiel, Delia
    Sanchez-Dominguez, Gisela
    Garcia-Villarejo, Mariana
    Olivares-Perez, Cesar
    Hernandez-Constantino, Angel
    Gonzalez-Santiago, Acitlalin
    Clara-Altamirano, Miguel
    Arela-Quispe, Liz
    Prada-Ortega, Diddier
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [37] Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a
    Shi, Huihui
    Liu, Liya
    Deng, Xueli
    Xing, Xiaoyu
    Zhang, Yan
    Rebecca, Yemeli Djouda
    Han, Liping
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [38] Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a
    Huihui Shi
    Liya Liu
    Xueli Deng
    Xiaoyu Xing
    Yan Zhang
    Yemeli Djouda Rebecca
    Liping Han
    Journal of Ovarian Research, 17
  • [39] Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125
    McKinnon, Brett
    Mueller, Michael D.
    Nirgianakis, Konstantinos
    Bersinger, Nick A.
    MOLECULAR MEDICINE REPORTS, 2015, 12 (04) : 5179 - 5184
  • [40] The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
    Micu, Romeo
    Gaia-Oltean, Adriana Maria Ioana
    Budisan, Livia
    Braicu, Cornelia
    Irimie, Alexandru
    Berindan-Neagoe, Ioana
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2023, 64 (02): : 159 - 164